Body mass index, physical activity, and serum markers of inflammation, immunity, and insulin resistance

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 12, 2014, Pages 2840-2849

  Kitahara, Cari M ^a   Trabert, Britton ^a   Katki, Hormuzd A ^a   Chaturvedi, Anil K ^a   Kemp, Troy J ^b   Pinto, Ligia A ^b   Moore, Steven C ^a   Purdue, Mark P ^a   Wentzensen, Nicolas ^a   Hildesheim, Allan ^a   Shiels, Meredith S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; BIOLOGICAL MARKER; C PEPTIDE; C REACTIVE PROTEIN; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INSULIN; LEPTIN; MACROPHAGE INFLAMMATORY PROTEIN 3BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 4; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CANCER PATIENT; CASE CONTROL STUDY; CLINICAL EVALUATION; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; IMMUNITY; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLEX POLYMERASE CHAIN REACTION; NONHODGKIN LYMPHOMA; OBESITY; OVARY CANCER; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; RISK FACTOR; SELF REPORT; SERUM; SMOKING; BLOOD; IMMUNOLOGY; MIDDLE AGED; MOTOR ACTIVITY;

AGED; BIOMARKERS; BODY MASS INDEX; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; MIDDLE AGED; MOTOR ACTIVITY; RISK FACTORS;

EID: 84919337982     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0699-T     Document Type: Article

References (34)

1. Gregor MF, Hotamisligil GS Inflammatory mechanisms in obesity. Annu Rev Immunol 2011; 29: 415-45.
2. Aroor AR, McKarns S, Demarco V.G., Jia G., Sowers JR. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism 2013; 62: 1543-52.
3. van Kruijsdijk R.C., van der Wall E, Visseren FL. Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev 2009; 18: 2569-78.
4. Khandekar MJ, Cohen P, Spiegelman BM Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011; 11: 886-95.
5. Fontes JD, Yamamoto JF, Larson M.G., Wang N., Dallmeier D, Rienstra M, et al Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. Atherosclerosis 2013; 228: 217-23.
6. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. Diabetes Res Clin Pract 2005; 69: 29-35.
7. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M., Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA 2003; 289:1799-804.
8. Mora S, Lee IM, Buring J.E., Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular bio-markers in women. JAMA 2006; 295: 1412-9.
9. Ertek S, Cicero A. Impact of physical activity on inflammation: effects on cardiovascular disease risk and other inflammatory conditions. Arch Med Sci 2012; 8: 794-804.
10. Hamer M, Sabia S, Batty G.D., Shipley MJ, Tabàk AG, Singh-Manoux A, et al. Physical activity and inflammatory markers over 10 years: follow-up in men and women from the Whitehall II cohort study. Circulation 2012; 126: 928-33.
11. Dossus L, Rinaldi S, Becker S., Lukanova A, Tjonneland A, Olsen A., et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case-control study. Endocr Relat Cancer 2010; 17: 1007-19.
12. Wang T, Rohan TE, Gunter M.J., Xue X, Wactawski-Wende J, Rajpathak SN, et al. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev 2011; 20: 971-7.
13. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ C-reactive protein and the risk of incidence colorectal cancer. JAMA 2004; 291: 585-90.
14. Chaturvedi AK, Moore SC, Hildesheim A. Invited commentary: circulating inflammation markers and cancer risk - implications for epidemiologic studies. Am J Epidemiol 2013; 177: 14-19.
15. Prorok PC, Andriole GL, Bresalier R.S., Buys SS, Chia D, Crawford ED, et al Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21:273S-309S.
16. Purdue MP, Hofmann JN, Kemp T.J., Chaturvedi AK, Lan Q, Park JH, et al A prospective study of 67 serum immune and inflammation markers and risk of non-Hodgkin lymphoma. Blood 2013; 122: 951-7.
17. Shiels MS, Pfeiffer RM, Hildesheim A, Engels E.A., Kemp TJ, Park JH, et al. Circulating inflammation markers and prospective risk of lung cancer. J Natl Cancer Inst 2013; 105: 1871-80.
18. Chaturvedi AK, Kemp TJ, Pfeiffer R.M., Biancotto A., Williams M, Munuo S, et al Evaluation of multiplexed cytokine and inflammation marker measurements: a methodologic study. Cancer Epidemiol Biomarkers Prev 2011; 20: 1902-11.
19. Korn EL, Graubard BI Analysis of health surveys. 1st ed. New York, NY: John Wiley & Sons; 1999.
20. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
21. Støer N.C., Samuelsen SO Inverse probability weighting in nested case-control studies with additional matching - a simulation study. Stat Med 2013; 32: 5328-39.
22. Ruige JB, Dekker JM, Blum W.F., Stehouwer CD, Nijpels G, Mooy J, et al Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study. Diabetes Care 1999; 22: 1097-104.
23. Adamska A, Nikolajuk A, Karczewska-Kupczewska M, Kowalska I., Otziomek E, Gorska M, et al Relationships between serum adiponec-tin and soluble TNF-a receptors and glucose and lipid oxidation in lean and obese subjects. Acta Diabetol 2012; 49: 17-24.
24. Hou X, Sun L, Li Z., Mou H, Yu Z, Li H., et al. Association of amylin with inflammatory markers and metabolic syndrome in apparently healthy Chinese. PLoS One 2011; 6:e24815.
25. Neilson HK, Robson PJ, Friedenreich C.M., Csizmadi I. Estimating activity energy expenditure: how valid are physical activity questionnaires? Am J Clin Nutr 2008; 87: 279-91.
26. Tourniaire F, Romier-Crouzet B, Lee J.H., Marcotorchino J., Gouranton E, Salles J, et al Chemokine expression in inflamed adipose tissue is mainly mediated by NF-kB. PLoS One 2013; 8:e66515.
27. Gallagher KA, Liu ZJ, Xiao M, Chen H., Goldstein LJ, Buerk DG, et al. Diabetic impairments in NO-mediated endothelial progenitor cell mobilization and homing are reversed by hyperoxia and SDF-1 alpha. J Clin Invest 2007; 117: 1249-59.
28. Juge-Aubry C.E., Somm E, Giusti V., Pernin A, Chicheportiche R, Verdumo C., et al. Adipose tissue is a major source of interleukin-1 receptor antagonist: upregulation in obesity and inflammation. Diabetes 2003; 52: 1104-10.
29. Heikkilä K, Harris R, Lowe G, Rumley A, Yarnell J, Gallacher J, et al. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-anal-ysis. Cancer Causes Control 2009; 20: 15-26.
30. Grote VA, Kaaks R, Nieters A., Tjønneland A, Halkjær J, Overvad K., et al. Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 2012; 106: 1866-74.
31. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005; 14: 2413-8.
32. Chan AT, Ogino S, Giovannucci E.L., Fuchs CS. Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs. Gastroenterology 2011; 140: 799-808.
33. Gross AL, Newschaffer CJ, Hoffman-Bolton J, Rifai N., Visvanathan K. Adipocytokines, inflammation, and breast cancer risk in postmeno-pausal women: a prospective study. Cancer Epidemiol Biomarkers Prev 2013; 22: 1319-24.
34. Ollberding NJ, Kim Y, Shvetsov Y.B., Wilkens LR, Franke AA, Cooney RV, et al Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila) 2013; 6: 188-95.